Loading...
Loading...
BOLT| Name | Value |
|---|---|
| Revenues | 1.3M |
| Cost of Revenue | 15.4M |
| Gross Profit | -14.2M |
| Operating Expense | 19.9M |
| Operating I/L | -22.6M |
| Other Income/Expense | 1.4M |
| Interest Income | 1.4M |
| Pretax | -21.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -21.2M |
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company's product pipeline includes BDC-1001, a Phase I/II clinical trial drug for HER2-expressing solid tumors; BDC-2034, a program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program designed to repolarize cells in the tumor microenvironment. Additionally, the company is developing a programmed cell death-ligand 1 program for nonresponsive tumors. These innovative therapies demonstrate Bolt Biotherapeutics' commitment to advancing cancer treatment through targeted immunotherapies.
